Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Payables (2016 - 2026)

Heron Therapeutics filings provide 16 years of Payables readings, the most recent being $9.0 million for Q1 2026.

  • On a quarterly basis, Payables fell 27.27% to $9.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.0 million, a 27.27% decrease, with the full-year FY2025 number at $9.0 million, down 23.19% from a year prior.
  • Payables hit $9.0 million in Q1 2026 for Heron Therapeutics, roughly flat from $9.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $161.8 million in Q2 2025 to a low of $559000.0 in Q4 2023.
  • Median Payables over the past 5 years was $9.0 million (2026), compared with a mean of $16.3 million.
  • Biggest five-year swings in Payables: soared 4507.14% in 2022 and later tumbled 85.82% in 2023.
  • Heron Therapeutics' Payables stood at $3.2 million in 2022, then crashed by 82.67% to $559000.0 in 2023, then surged by 1994.63% to $11.7 million in 2024, then dropped by 23.19% to $9.0 million in 2025, then fell by 0.27% to $9.0 million in 2026.
  • The last three reported values for Payables were $9.0 million (Q1 2026), $9.0 million (Q4 2025), and $12.0 million (Q3 2025) per Business Quant data.